The dual nature of specific immunological activity of tumor-derived gp96 preparations.
about
Heat Shock Protein-Peptide and HSP-Based Immunotherapies for the Treatment of CancerFunctions of heat shock proteins in pathways of the innate and adaptive immune systemClients and Oncogenic Roles of Molecular Chaperone gp96/grp94Identification of chaperones as essential components of the tumor rejection moieties of cancersIdentification of the peptide-binding site in the heat shock chaperone/tumor rejection antigen gp96 (Grp94).Glycoprotein 96 can chaperone both MHC class I- and class II-restricted epitopes for in vivo presentation, but selectively primes CD8+ T cell effector function.HSPs drive dichotomous T-cell immune responses via DNA methylome remodelling in antigen presenting cells.ATF3 plays a key role in Kdo2-lipid A-induced TLR4-dependent gene expression via NF-κB activation.High efficiency CD91- and LOX-1-mediated re-presentation of gp96-chaperoned peptides by MHC II molecules.Biological and clinical developments in melanoma vaccines.HSPPC-96: a personalised cancer vaccine.A study on the differential protein profiles in liver cells of heat stress rats with and without turpentine treatmentDendritic cell-based vaccines: barriers and opportunitiesGp96 SIV Ig immunization induces potent polyepitope specific, multifunctional memory responses in rectal and vaginal mucosaHeat-shock protein-based vaccines for cancer and infectious disease.Facets of heat shock protein 70 show immunotherapeutic potential.Membrane-bound HSP70-engineered myeloma cell-derived exosomes stimulate more efficient CD8(+) CTL- and NK-mediated antitumour immunity than exosomes released from heat-shocked tumour cells expressing cytoplasmic HSP70.The stress protein gp96 is not an activator of resting rat bone marrow-derived dendritic cells, but is a costimulator and activator of CD3+ T cells.Heat shock proteins and cancer vaccines: developments in the past decade and chaperoning in the decade to comeAdministration of the stress protein gp96 prolongs rat cardiac allograft survival, modifies rejection-associated inflammatory events, and induces a state of peripheral T-cell hyporesponsivenessDNA vaccines expressing antigens with a stress protein-capturing domain display enhanced immunogenicity.CD91-dependent programming of T-helper cell responses following heat shock protein immunization.DNA vaccines coding for heat-shock proteins (HSPs): tools for the activation of HSP-specific regulatory T cells.A non-receptor-mediated mechanism for internalization of molecular chaperonesReceptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways.Heat shock protein vaccines: from bench to bedside.Identification of the cellular sentinels for native immunogenic heat shock proteins in vivo.Glycoprotein 96-mediated presentation of human immunodeficiency virus type 1 (HIV-1)-specific human leukocyte antigen class I-restricted peptide and humoral immune responses to HIV-1 p24.Caught with their PAMPs down? The extracellular signalling actions of molecular chaperones are not due to microbial contaminants.The role of heat shock proteins in antigen cross presentation.Challenges in the development of an autologous heat shock protein based anti-tumor vaccine.A tale of two pities: autologous melanoma vaccines on the brink.Glycoprotein (gp) 96 expression: induced during differentiation of intestinal macrophages but impaired in Crohn's disease.Improving vaccine efficacy against malignant gliomaFusion proteins of Hsp70 with tumor-associated antigen acting as a potent tumor vaccine and the C-terminal peptide-binding domain of Hsp70 being essential in inducing antigen-independent anti-tumor response in vivo.Effect of adenovirus-mediated heat shock protein expression and oncolysis in combination with low-dose cyclophosphamide treatment on antitumor immune responses.Comparison of the anti-tumor effects of various whole-body hyperthermia protocols: correlation with HSP 70 expression and composition of splenic lymphocytes.Secretory heat-shock protein as a dendritic cell-targeting molecule: a new strategy to enhance the potency of genetic vaccines.Characterization of a receptor for heat shock protein 70 on macrophages and monocytes.A role for the heat shock protein-CD91 axis in the initiation of immune responses to tumors.
P2860
Q26747392-157CAF12-8551-479D-9F09-8B902E84CA27Q26830705-64276618-D95A-4D1E-93EA-11885352224FQ28075479-DD2B16C4-7D36-4228-A73F-F9B825A9F12FQ28728195-B46C935E-1FE0-42C6-A8DB-AF795D30F35EQ30840326-DD474EB5-A336-41C1-9264-7A68591309B6Q33756673-8ED0AC9D-B599-4C00-9BEC-69319C9EF7C1Q33766735-D8E5E482-3D6E-4A4E-B96D-C156ABDD2D05Q33769856-8BA37C7A-B792-4B2C-81AE-F01CD922D28DQ34240327-72D5E772-CA51-46DB-A8F2-FE0CCF34C415Q34452007-D23F7CD8-3245-433F-8BAB-33FE41A1768FQ34452027-CD86D374-4C3F-419C-B68E-C3FAA30AC373Q34602725-9DA65C87-566A-4531-B582-373558ABC162Q34661797-A0141452-2C0C-4DB1-8E7F-71BC3D506C0BQ34727695-76802CF1-BCDB-4E19-ADE0-5BBF597EA78CQ34768299-C861AC85-B646-46F5-8BD5-2128016D05E9Q35206769-811DAE63-8853-422A-B2D6-5A7F408AF366Q35216417-B2E472AC-CF8A-4237-8512-C393E963BA9BQ35239568-C98609ED-775E-4112-8841-7D2ED613ACD4Q35624884-46BBE81D-77B0-463D-85DE-66D78FD28260Q35753012-3EDA540A-EEED-4361-957A-A9AC5707D618Q35826374-1C7C4071-D2ED-4BCE-8AA7-0E1AFE9D00F9Q35973873-FBFD8F95-5F17-4A0D-B6A6-7E581266734AQ36150452-5B06CB70-C59A-4B2C-983F-91846FCDC701Q36389477-FB07B56B-E6EE-4143-B80D-55B9AEFDC051Q36404658-EC2AF9EB-43D3-4BED-9F94-384B5A680B4AQ36684490-DD62822F-57D4-480F-B164-8FED2DD48D7CQ37240798-8C207DFF-C1C0-45A2-BEF2-E3B0DC4F5CE5Q37410002-8B1C0D26-45D2-4F06-8A17-157DCFAF7E0EQ37592040-949B6A42-7507-454A-B465-28374070A003Q38008364-EE216061-11DF-42A2-A415-10FD9E3743DEQ38031382-ADB7EC58-1AF8-49E0-ACA7-AF4B649961A7Q38031384-28837363-46EF-4B27-9161-B9A8AEB24490Q38325093-527F2DDC-B311-4F6F-AF30-776A556FE8D2Q38953024-4005EE6B-2CB8-4C51-BC75-D5517FE87130Q40226012-7747853B-C793-42C0-82DF-D07C9030C272Q40327515-9C93CB35-465C-4646-B95C-D71B135ADAD9Q40379012-9FD607E1-C994-4159-983D-DEFBCF4159D9Q40566671-FF7FCAB2-E6DF-4A65-A36C-D880220C1F84Q40824757-A4226E6D-A74B-45B9-9B8D-A063BB9EDE87Q42056136-1D4FA637-0EF9-43D2-BA6A-50DBB139C355
P2860
The dual nature of specific immunological activity of tumor-derived gp96 preparations.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
The dual nature of specific immunological activity of tumor-derived gp96 preparations.
@ast
The dual nature of specific immunological activity of tumor-derived gp96 preparations.
@en
type
label
The dual nature of specific immunological activity of tumor-derived gp96 preparations.
@ast
The dual nature of specific immunological activity of tumor-derived gp96 preparations.
@en
prefLabel
The dual nature of specific immunological activity of tumor-derived gp96 preparations.
@ast
The dual nature of specific immunological activity of tumor-derived gp96 preparations.
@en
P2093
P2860
P356
P1476
The dual nature of specific immunological activity of tumor-derived gp96 preparations.
@en
P2093
P K Srivastava
R Y Chandawarkar
P2860
P304
P356
10.1084/JEM.189.9.1437
P407
P577
1999-05-01T00:00:00Z